@entity31240 Reduces Cancer-induced Bone XXXX Possibly Through Inhibition of Osteoclastogenesis in @entity35 Cancer-induced Bone @entity158 Model.

@entity5272 @entity9248 @entity462 @entity31240 @entity3478 @entity30211 @entity5 @entity460 @entity158 @entity35
BACKGROUND: Calpain, a @entity460 -dependent @entity462 protease, has been demonstrated to regulate osteoclastogenesis, which is considered one of the major reasons for @entity3478 ( @entity3478 ). In the present study, @entity31240 was applied in a @entity35 @entity3478 model to determine whether it could reduce @entity3478 through regulation of osteoclastogenesis activity. METHODS: A @entity35 @entity3478 model was established with intratibial injection of Walker 256 cells. Then, the efficacy of intraperitoneal administered @entity31240 III ( @entity30211 , 1 mg/kg) on mechanical withdrawal threshold (MWT) of bilateral hind paws was examined on postoperative days (PODs) 2, 5, 8, 11, and 14. On POD 14, the @entity31240 's effect on @entity5 bone @entity5272 -resistant acid phosphatase (TRAP) stain and radiology was also carefully investigated. RESULTS: @entity158 behavioral tests in @entity35 showed that the @entity31240 effectively attenuated MWTs of both the surgical side and contralateral side hind paws on POD 5, 8, and 11 (P < 0.05). TRAP-positive cell count of the surgical side bone was significantly decreased in the @entity31240 group compared with the vehicle group (P < 0.05). However, bone resorption and destruction measured by radiographs showed no difference between the two groups. CONCLUSIONS: @entity31240 can effectively reduce @entity3478 of both the surgical side and nonsurgical side after @entity5 injection in a @entity35 @entity3478 model. It may be due to the inhibition of @entity9248 -induced osteoclastogenesis. Whether a @entity31240 could be a novel therapeutic target to treat @entity3478 needs further investigation.
